...
首页> 外文期刊>Cell death & disease. >Generation of qualified clinical-grade functional hepatocytes from human embryonic stem cells in chemically defined conditions
【24h】

Generation of qualified clinical-grade functional hepatocytes from human embryonic stem cells in chemically defined conditions

机译:在化学定义的条件下,来自人胚胎干细胞的合格临床级功能性肝细胞

获取原文

摘要

Hepatocytes have been successfully generated from human pluripotent stem cells (hPSCs). However, the cost-effective and clinical-grade generation of hepatocytes from hPSCs still need to be improved. In this study, we reported the production of functional hepatocytes from clinical-grade human embryonic stem cells (hESCs) under good manufacturing practice (GMP) requirements. We sequentially generated primitive streak (PS), definitive endoderm (DE), hepatoblasts and hepatocyte-like cells (HLCs) from hESCs in the different stages with completely defined reagents. During hepatoblast differentiation, dimethyl sulfoxide (DMSO), transferrin, L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate (Vc-Mg), insulin, and sodium selenite were used instead of cytokines and FBS/KOSR. Then, hepatoblasts were differentiated into HLCs that had a typical hepatocyte morphology and possessed characteristics of mature hepatocytes, such as metabolic-related gene expression, albumin secretion, fat accumulation, glycogen storage, and inducible cytochrome P450 activity in vitro. HLCs integrated into the livers of Tet-uPA Rag2-/- Il2rg-/- (URG) mice, which partially recovered after transplantation. Furthermore, a series of biosafety-related experiments were performed to ensure future clinical applications. In conclusion, we developed a chemically defined system to generate qualified clinical-grade HLCs from hESCs under GMP conditions. HLCs have been proven to be safe and effective for treating liver failure. This efficient platform could facilitate the treatment of liver diseases using hESC-derived HLCs transplantation.
机译:已经从人多能干细胞(HPSC)成功地生成了肝细胞。然而,需要改善来自HPSCS的成本效益和临床级生成肝细胞。在这项研究中,我们报道了在良好的制造实践(GMP)要求下从临床级人胚胎干细胞(HESC)的功能性肝细胞的生产。在具有完全定义的试剂的不同阶段中,我们依次产生的原始条纹(PS),最终的内胚层(DE),肝细胞和肝细胞样细胞(HLC),具有完全定义的试剂。在肝脏分化期间,使用二甲基亚砜(DMSO),转铁蛋白,L-抗坏血酸2-磷酸级盐水合物(VC-MG),胰岛素,亚硒酸钠代替细胞因子和FBS / KOSR。然后,将肝细胞分化为具有典型肝细胞形态的HLC和具有成熟肝细胞的特征,例如代谢相关的基因表达,白蛋白分泌,脂肪积聚,糖原储存和体外诱导的细胞色素P450活性。 HLC集成到TET-UPA RAG2 - / - IL2RG - / - / - (URG)小鼠的肝脏中,该小鼠部分回收。此外,进行了一系列生物安全相关的实验以确保未来的临床应用。总之,我们开发了一种化学定义的系统,以在GMP条件下从HESC产生合格的临床级HLC。已经证明HLCS可以安全可有效治疗肝脏衰竭。这种有效平台可以促进使用HESC衍生的HLC移植治疗肝脏疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号